SUTRO BIOPHARMA, INC.
SUTRO BIOPHARMA, INC. (STRO): 11 pipeline candidates · ~14 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.4 months
D/E -4.62 · 0% dilution
Lead: Phase 2
11 candidates
N/A
N/A
A transparent, data-derived signal for SUTRO BIOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$470.8M
Cash
$74.5M
Quarterly Burn
$42.3M
Runway
14.4 mo
Revenue
$14.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| Luveltamab tazevibulin | Phase 2 |
| MK-1484 | Phase 1 |
| Pegfilgrastim | Phase 2 |
| STRO-001 | Phase 1 |
| STRO-002 | Phase 2 |
| STRO-002 (luveltamab tazevibulin, luvelta) | Phase 2 |
| STRO-003 | Phase 1 |
| STRO-004 | Phase 1 |
| stro-006 | Phase 1 |
| stro-227 | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
69
Total value held
$352.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,440,884 | $35.9M |
| perceptive advisors llc | 1,430,614 | $35.6M |
| bvf inc/il | 1,251,788 | $31.2M |
| affinity asset advisors, llc | 1,069,519 | $26.6M |
| samsara biocapital, llc | 1,062,872 | $26.5M |
| woodline partners lp | 914,882 | $22.8M |
| orbimed advisors llc | 801,144 | $20.0M |
| eventide asset management, llc | 715,307 | $17.8M |
| ra capital management, l.p. | 715,307 | $17.8M |
| adar1 capital management, llc | 524,441 | $13.1M |
Showing top 10 of 69 institutional holders of SUTRO BIOPHARMA, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SUTRO BIOPHARMA, INC.'s pipeline?
SUTRO BIOPHARMA, INC. (STRO) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SUTRO BIOPHARMA, INC.'s lead drug candidate?
SUTRO BIOPHARMA, INC.'s most advanced tracked candidate is Luveltamab tazevibulin (Phase 2) for Acute Myeloid Leukemia (AML); Lung Cancer; Ovarian Cancer.
What is SUTRO BIOPHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SUTRO BIOPHARMA, INC. has approximately 14.4 months of cash runway.
What is SUTRO BIOPHARMA, INC.'s market capitalization?
SUTRO BIOPHARMA, INC.'s market capitalization is approximately $470.8M.
Who is the CEO of SUTRO BIOPHARMA, INC.?
Ms. Jane Chung R.Ph. is the chief executive officer of SUTRO BIOPHARMA, INC. (STRO).
Get the full picture on SUTRO BIOPHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.